POM-V Prescription Required Companion Animal

Telmitraxx 4 mg/ml Oral Solution for Cats

Active ingredient: Telmisartan

Form

Liquid

Species

Cats

Manufacturer

Alfasan Nederland B.V.

VMD MA No.

36408/3019

What it's used for

Reduction of proteinuria associated with chronic kidney disease (CKD) in cats. Treatment of systemic hypertension in cats

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Telmisartan

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Telmitraxx 4 mg/ml Oral Solution for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Reduction of proteinuria associated with chronic kidney disease (CKD) in cats.
Treatment of systemic hypertension in cats

Do not use during pregnancy or lactation (see also section 4.7).
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Cats:
Rare
(1 to 10 animals / 10,000
animals treated):
Gastrointestinal signs (regurgitation
, vomiting
diarrhoea
2)
.
Elevated renal parameters (creatinine and/or
blood urea nitrogen), chronic renal failure.
Very rare
(<1 animal / 10,000
animals treated, including
isolated reports):
Elevated liver enzymes
Decreased red blood cell counts (see section
4.5).
Mild and intermittent
Vomiting and diarrhoea are commonly reported when given at the initial
treatment dose of 2 mg/kg for systemic hypertension. Mild and transient
Values normalised within a few days following cessation of therapy.
Reporting adverse events is important. It allows continuous safety monitoring of
a veterinary medicinal product. Reports should be sent, preferably via a
veterinarian, to either the marketing authorisation holder or its local
representative or the national competent authority via the national reporting
system. See also the last section of the package leaflet for respective contact
details.

The safety and efficacy of telmisartan for the management of systemic
hypertension above 200 mmHg has not been investigated.

Revised: September 2025
AN:01495/2025

i). Special precautions for use in animals
The safety and efficacy of telmisartan has not been tested in cats under the age
of 6 months.
It is good clinical practice to monitor the blood pressure of cats receiving the
veterinary medicinal product which are under anaesthesia.
Due to the mode of action of the veterinary medicinal product, transient
hypotension may occur. Symptomatic treatment, e.g. fluid therapy, should be
provided in case of any clinical signs of hypotension. The dosage of telmisartan
should be reduced if systolic blood pressure (SBP) is consistently lower than 120
mmHg or if there are concurrent signs of hypotension.
As known from substances acting on the Renin-Angiotensin-Aldosterone System
(RAAS), a slight decrease in red blood cell count may occur. Red blood cell
count should be monitored during therapy.
Substances acting on the RAAS may lead to a reduction in glomerular filtration
rate and worsening renal function in cats with severe kidney disease. The safety
and efficacy of telmisartan in such patients has not been investigated. When
using this product in cats with severe kidney disease, it is advisable to monitor
renal function (plasma creatinine concentration).
In cats with hypertension it is good clinical practice to regularly monitor blood
pressure.
ii). Special precautions to be taken by the person administering the veterinary
medicinal product to animals
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Avoid eye contact. In case of accidental eye contact, rinse eyes with water.
Wash hands after use.
Pregnant women should take special care to avoid contact with the product
because substances acting on the RAAS, such as Angiotensin Receptor
Blockers (ARBs) and ACE inhibitors (ACEis), have been found to affect the
unborn child during pregnancy in humans.
People with hypersensitivity to telmisartan or other sartans/ARBs should avoid
contact with the veterinary medicinal product.
iii) Special precautions for the protection of the environment
Not applicable.

Revised: September 2025
AN:01495/2025

No drug-drug interactions are known from available data in cats with CKD and/or
hypertension for the use of telmisartan and other medicinal products that lower
blood pressure (such as amlodipine) or interfere with RAAS (such as ARBs or
ACEis). The combination of such agents may lead to additive hypotensive
effects or may alter renal function.
During concomitant therapy with amlodipine at the recommended dose for the
reduction of proteinuria associated with chronic kidney disease (CKD) in cats, no
clinical evidence of hypotension was observed.

This veterinary medicinal product does not require any special storage
conditions.

Systemic hypertension associated with CKD – amounts to be administered
once daily:
The dosing regimen for hypertensive cats with concomitant chronic kidney
disease is as described above for systemic hypertension except that for these
cats the recommended minimum effective dose is 1 mg/kg.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
After administration of up to 5 mg/kg body weight for 6 months to young adult
healthy cats, adverse reactions observed were consistent with those mentioned
in section 4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.